{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:13:08Z","timestamp":1758845588688,"version":"3.44.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI139633-04S1","T32AI007512"],"award-info":[{"award-number":["R01AI139633-04S1","T32AI007512"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK130465"],"award-info":[{"award-number":["R01DK130465"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jaci.2021.12.775","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T10:50:13Z","timestamp":1640343013000},"page":"569-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in clinical outcomes: What we have learned during the COVID-19 pandemic"],"prefix":"10.1016","volume":"149","author":[{"given":"Amer","family":"Al-Musa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna","family":"LaBere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saddiq","family":"Habiballah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-2657","authenticated-orcid":false,"given":"Janet","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.12.775_bib1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2020.09.017","article-title":"Asthma-associated risk for COVID-19 development","volume":"146","author":"Skevaki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib2","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jaci.2020.11.002","article-title":"Integrated-omics endotyping of infants with rhinovirus bronchiolitis and risk of childhood asthma","volume":"147","author":"Raita","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib3","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.jaci.2021.03.011","article-title":"Asthma and viruses: a focus on rhinoviruses and SARS-CoV-2","volume":"147","author":"Padayachee","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jaci.2021.10.001","article-title":"Advances in asthma: new understandings of asthma\u2019s natural history, risk factors, underlying mechanisms, and clinical management","volume":"148","author":"Miller","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib6","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.775_bib7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jaci.2020.07.026","article-title":"Asthma among hospitalized patients with COVID-19 and related outcomes","volume":"146","author":"Lovinsky-Desir","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaci.2020.05.049","article-title":"Asthmatic patients in COVID-19 outbreak: few cases despite many cases","volume":"146","author":"Caminati","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2020.04.061","article-title":"Prevalence of comorbid asthma in COVID-19 patients","volume":"146","author":"Butler","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2020.07.018","article-title":"Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19","volume":"146","author":"Wang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaci.2020.05.011","article-title":"The bimodal SARS-CoV-2 outbreak in Italy as an effect of environmental and allergic causes","volume":"146","author":"Chirumbolo","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000510953","article-title":"Does asthma increase the mortality of patients with COVID-19? A\u00a0systematic review and meta-analysis","volume":"182","author":"Wang","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib13","doi-asserted-by":"crossref","first-page":"21805","DOI":"10.1038\/s41598-020-77791-8","article-title":"Impact of comorbid asthma on severity of coronavirus disease (COVID-19)","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.12.775_bib14","first-page":"1","article-title":"Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients","author":"Hussein","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2021.12.775_bib15","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.jaip.2021.06.036","article-title":"Association between pediatric asthma and positive tests for SARS-CoV-2 in the District of Columbia","volume":"9","author":"Margolis","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2020.12.045","article-title":"Eosinophilia in asthma patients is protective against severe COVID-19 illness","volume":"9","author":"Ferastraoaru","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib17","first-page":"1","article-title":"Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: systematic review and meta-analysis","author":"Sunjaya","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2021.12.775_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jaci.2020.06.010","article-title":"Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19","volume":"146","author":"Chhiba","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib19","first-page":"1","article-title":"COVID-19 severity in asthma patients: a multi-center matched cohort study","author":"Robinson","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2021.12.775_bib20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/all.14601","article-title":"Asthmatic patients and COVID-19: different disease course?","volume":"76","author":"Alberca","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.775_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaci.2020.06.001","article-title":"Association of asthma and its genetic predisposition with the risk of severe COVID-19","volume":"146","author":"Zhu","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03142-2020","article-title":"The impact of COVID-19 on patients with asthma","volume":"57","author":"Izquierdo","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.12.775_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jaci.2020.05.033","article-title":"Molecular mechanisms and epidemiology of COVID-19 from an allergist\u2019s perspective","volume":"146","author":"Hosoki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaci.2020.05.013","article-title":"ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma\u2014implications for COVID-19","volume":"146","author":"Bradding","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2020.05.051","article-title":"Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype","volume":"146","author":"Camiolo","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib27","doi-asserted-by":"crossref","first-page":"AB40","DOI":"10.1016\/j.jaci.2020.12.177","article-title":"COVID-19, severe asthma and biologicals targeting type 2 inflammation: results\u00a0in a third-level hospital in Madrid, Spain","volume":"147","author":"Estirado","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2020.04.021","article-title":"Eosinophil responses during COVID-19 infections and coronavirus vaccination","volume":"146","author":"Lindsley","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jaci.2020.08.026","article-title":"The intersect of genetics, environment, and microbiota in asthma\u2014perspectives and challenges","volume":"147","author":"Tang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib31","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the Seattle region\u2014case series","volume":"382","author":"Bhatraju","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib32","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/j.jaip.2021.07.030","article-title":"Asthma disease status, COPD, and COVID-19 severity in a large multiethnic population","volume":"9","author":"Huang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2021.06.006","article-title":"COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence","volume":"148","author":"Adir","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib34","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jaip.2020.03.012","article-title":"COVID-19: pandemic contingency planning for the allergy and immunology clinic","volume":"8","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaci.2020.04.046","article-title":"COVID-19: time to embrace MDI+ valved-holding chambers","volume":"146","author":"Amirav","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jaci.2020.04.003","article-title":"An academic allergy unit during COVID-19 pandemic in Italy","volume":"146","author":"Malipiero","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib37","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2020.05.012","article-title":"A phased approach to resuming suspended allergy\/immunology clinical services","volume":"8","author":"Searing","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-020-00509-y","article-title":"Asthma and COVID-19: a systematic review","volume":"17","author":"Mendes","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.614086","article-title":"Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel","volume":"11","author":"Marcus","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib41","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib42","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10875-021-01065-9","article-title":"COVID-19 in patients with primary immunodeficiency","volume":"41","author":"Esenboga","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10875-020-00928-x","article-title":"Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency","volume":"41","author":"Delavari","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaci.2020.09.020","article-title":"Severe SARS-CoV-2 disease in the context of a NF-\u03baB2 loss-of-function pathogenic variant","volume":"147","author":"Abraham","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib46","doi-asserted-by":"crossref","unstructured":"Abyazi ML, Bell KA, Gyimesi G, Baker TS, Byun M, Ko HM, et\u00a0al. Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications [published online ahead of print June 17, 2021]. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2021.06.008.","DOI":"10.1016\/j.jaci.2021.06.008"},{"key":"10.1016\/j.jaci.2021.12.775_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaci.2018.06.012","article-title":"CVID patients with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses","volume":"143","author":"Romberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaip.2020.11.006","article-title":"COVID-19 infection in 10 common variable immunodeficiency patients in New York City","volume":"9","author":"Cohen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib49","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2014.11.029","article-title":"Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency","volume":"135","author":"Wehr","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"Clinical picture and treatment of 2212 patients with common variable immunodeficiency","volume":"134","author":"Gathmann","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/ACI.0000000000000786","article-title":"Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity","volume":"21","author":"Tangye","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2020.11.007","article-title":"Marked changes in innate immunity associated with a mild course of COVID-19 in identical twins with athymia and absent circulating T cells","volume":"147","author":"Colmenero-Vel\u00e1zquez","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib53","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of genetic variants among young men with severe COVID-19","volume":"324","author":"van der Made","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2021.12.775_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719115","article-title":"Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19","volume":"12","author":"Solanich","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in \u223c1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaci.2021.12.775_bib57","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib58","article-title":"Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs","volume":"218","author":"Lopez","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaci.2021.03.034","article-title":"Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis","volume":"148","author":"Lemarquis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaci.2021.12.775_bib61","article-title":"Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19","volume":"131","author":"Povysil","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.12.775_bib62","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41586-021-04103-z","article-title":"Exome sequencing and analysis of 454,787 UK Biobank participants","volume":"599","author":"Backman","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.12.775_bib63","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaci.2020.07.033","article-title":"Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1","volume":"146","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib64","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaci.2021.06.024","article-title":"Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)","volume":"148","author":"Chou","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2102605","article-title":"Multisystem inflammatory syndrome in children\u2014initial therapy and outcomes","volume":"385","author":"Son","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib66","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib68","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.jaci.2021.02.021","article-title":"IL-6\u2013based mortality prediction model for COVID-19: validation and update in multicenter and second wave cohorts","volume":"147","author":"Utrero-Rico","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2020.09.018","article-title":"IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study","volume":"147","author":"Galv\u00e1n-Rom\u00e1n","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaci.2020.08.031","article-title":"Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19","volume":"147","author":"Sims","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaci.2020.10.001","article-title":"COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department","volume":"147","author":"Van Singer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib72","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jaci.2021.03.047","article-title":"Distinct cytokine profiles associated with COVID-19 severity and mortality","volume":"147","author":"Dorgham","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaci.2020.05.003","article-title":"Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China","volume":"146","author":"Chen","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib74","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib75","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaci.2020.07.009","article-title":"IL-6\u2013based mortality risk model for hospitalized patients with COVID-19","volume":"146","author":"Laguna-Goya","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41420-021-00429-9","article-title":"Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients","volume":"7","author":"Awasthi","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jaci.2021.12.775_bib77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib78","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1038\/s41598-021-86676-3","article-title":"PaO2\/FiO2 and IL-6 are risk\u00a0factors of mortality for intensive care COVID-19 patients","volume":"11","author":"Gu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.12.775_bib79","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jaci.2021.12.775_bib80","doi-asserted-by":"crossref","first-page":"e2141","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in Covid-19: a systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jaci.2021.12.775_bib81","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaci.2021.05.032","article-title":"Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19","volume":"148","author":"Zaid","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib82","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1038\/s41467-021-25191-5","article-title":"The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients","volume":"12","author":"Perreau","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.12.775_bib83","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib84","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","article-title":"Type I IFN immunoprofiling in COVID-19 patients","volume":"146","author":"Trouillet-Assant","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib85","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.12.775_bib86","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaci.2021.12.775_bib87","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jaci.2008.02.026","article-title":"The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29","volume":"121","author":"Commins","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib88","first-page":"979","article-title":"IL-10-producing ILCs: molecular mechanisms and disease relevance","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib89","first-page":"58","article-title":"SOCS3, a major regulator of infection and inflammation","volume":"5","author":"Rottenberg","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib90","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/nsr\/nwaa037","article-title":"Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury","volume":"7","author":"Liu","year":"2020","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.jaci.2021.12.775_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6104054","article-title":"IL-10: a multifunctional cytokine in viral infections","volume":"2017","author":"Rojas","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaci.2021.12.775_bib92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41385-020-00355-6","article-title":"Genetic influences on viral-induced cytokine responses in the lung","volume":"14","author":"Forbester","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib94","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1038\/s41467-021-24360-w","article-title":"Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity","volume":"12","author":"Vanderbeke","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.12.775_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645850","article-title":"The effect of unconventional cytokine combinations on NK-cell responses to viral infection","volume":"12","author":"Ochayon","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib96","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1172\/JCI138554","article-title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent","volume":"130","author":"Mazzoni","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.12.775_bib97","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jcph.1795","article-title":"Differential binding of sarilumab and tocilizumab to IL-6R\u03b1 and effects of receptor occupancy on clinical parameters","volume":"61","author":"Xu","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2021.12.775_bib98","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.12.775_bib99","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in\u00a0patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib100","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib101","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Domingo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2021.12.775_bib103","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib104","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib105","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-021-01299-x","article-title":"Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19","volume":"35","author":"Gritti","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.12.775_bib106","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","article-title":"The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases","volume":"147","author":"Damsky","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib107","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2021.12.775_bib108","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib109","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib110","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/s41375-021-01266-6","article-title":"JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis","volume":"35","author":"Chen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2021.12.775_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.jaci.2021.12.775_bib112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib113","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jaci.2009.11.001","article-title":"Therapy of autoinflammatory syndromes","volume":"124","author":"Hoffman","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib114","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/ni.2457","article-title":"Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency","volume":"13","author":"Boisson","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib115","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jaci.2019.06.017","article-title":"Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1\u03b2 inhibition","volume":"144","author":"Gernez","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib116","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jaci.2011.05.023","article-title":"Successful canakinumab treatment identifies IL-1\u03b2 as a pivotal mediator in Schnitzler syndrome","volume":"128","author":"de Koning","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib117","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2009.11.016","article-title":"Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses","volume":"124","author":"Goldbach-Mansky","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib118","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2007.09.021","article-title":"IL-1 blockade in Schnitzler syndrome: ex\u00a0vivo findings correlate with clinical remission","volume":"121","author":"Ryan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib119","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease","volume":"146","author":"Pontali","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib120","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","article-title":"Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia","volume":"147","author":"Pontali","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib121","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","article-title":"Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study","volume":"147","author":"Bozzi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib122","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.jaci.2021.12.775_bib123","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaci.2021.12.775_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","year":"2021","journal-title":"NPJ Vacc"},{"key":"10.1016\/j.jaci.2021.12.775_bib127","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib128","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jaci.2021.08.016","article-title":"Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity","volume":"148","author":"Delmonte","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib129","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib130","doi-asserted-by":"crossref","unstructured":"Maltezou HC, Anastassopoulou C, Hatziantoniou S, Poland GA, Tsakris A. Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines [published online ahead or print November 27, 2021]. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.066.","DOI":"10.1016\/j.vaccine.2021.11.066"},{"key":"10.1016\/j.jaci.2021.12.775_bib131","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2021.12.775_bib132","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2021.01.004","article-title":"mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis","volume":"147","author":"Rama","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib133","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaci.2020.06.009","article-title":"Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: expert opinions","volume":"146","author":"Valent","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib134","doi-asserted-by":"crossref","unstructured":"Bruusgaard-Mouritsen MA, Jensen BM, Poulsen LK, Duus Johansen J, Garvey LH. Optimizing investigation of suspected allergy to polyethylene glycols [published online ahead or print May 28, 2021]. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.020.","DOI":"10.1016\/j.jaci.2021.05.020"},{"key":"10.1016\/j.jaci.2021.12.775_bib135","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib136","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/jamainternmed.2021.3779","article-title":"Safety\u00a0evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose","volume":"181","author":"Krantz","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib137","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamadermatol.2021.2114","article-title":"Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines","volume":"157","author":"Robinson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.12.775_bib138","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaci.2021.12.775_bib139","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jamadermatol.2021.1214","article-title":"Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series","volume":"157","author":"Johnston","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.12.775_bib140","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2021.06.026","article-title":"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination","volume":"148","author":"Tomayko","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib141","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","volume":"147","author":"Risma","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib142","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current\u00a0evidence and suggested approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J. Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.775_bib143","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2021012152","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know","volume":"138","author":"Arepally","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.12.775_bib144","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41577-021-00642-8","article-title":"Lessons from vaccine-induced immune thrombotic thrombocytopenia","volume":"21","author":"Kelton","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2021.12.775_bib145","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccination","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2021.12.775_bib146","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.775_bib147","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1056\/NEJMc2111305","article-title":"No correlation between anti-PF4 and anti\u2013SARS-CoV-2 antibodies after ChAdOx1 nCoV-19 vaccination","volume":"385","author":"Uzun","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921026865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921026865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:36:18Z","timestamp":1758792978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921026865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0091674921026865"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.12.775","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in clinical outcomes: What we have learned during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.12.775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}